The last two decades have seen unprecedented changes in the field of Neuro-Oncology. A new classification system for primary nervous system neoplasms has been established by the World Health Organization. Technological advances have led to our ability to diagnose brain tumors earlier and to treat them more effectively and with reduced morbidity using multimodality approaches incorporating surgery, radiation, and chemotherapy. Our rapidly evolving understanding of the molecular and genetic mechanisms leading to brain cancer now provides powerful prognostic and predictive information that drives therapeutic decisions and is stimulating novel treatment strategies.

This special issue of Hematology/Oncology Clinics of North America provides an up-to-date and concise review of the molecular pathogenesis, novel diagnostic strategies, current standards of care, and novel therapies of primary brain tumors and CNS metastases. The issue comprises contributions from experts from the multiple disciplines relevant to Neuro-Oncology and provides a reflection of their personal experiences and interpretation of published studies.

We thank everyone who has helped in the preparation of this issue. Most importantly, we thank the contributing authors whose work provides the substance of this special issue. It has been a privilege working with them and reading their contributions.
“first hand.” We are grateful to the staff at the editorial office, whose efforts assured timely completion.

Jill Lacy, MD
Department of Medicine
Section of Medical Oncology
Yale University School of Medicine
333 Cedar Street
New Haven, CT 06510, USA

Joachim M. Baehring, MD, DSc
Departments of Neurology, Neurosurgery, and Medicine
Yale University School of Medicine
Yale Brain Tumor Center
15 York Street
New Haven, CT 06510, USA

E-mail addresses:
jill.lacy@yale.edu (J. Lacy)
joachim.baehring@yale.edu (J.M. Baehring)